In light of growing evidence that MIF blockade can overcome resistance to ICI therapy in patients with melanoma, our data further suggests that MIF and DDT exhibit potential as therapeutic targets and biomarkers in predicting response to treatment and survival, with CD74:MIF and CD74:DDT offering promise as markers of ICI response in those undergoing treatment. Here, MIF is linked to melanoma.